Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704325 | 0.91 | CA1 (0.46) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL1703764 | 0.89 | CA1 (0.44) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL16442244 | 0.87 | CA1 (0.38) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL6050956 | 0.86 | CA1 (0.54) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL12102205 | 0.86 | GABRA1 (0.47) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL21477767 | 0.85 | PPARA (0.50) | CA1PPARACA2CA12CA7 | |
| SCHEMBL29764410 | 0.84 | CA1 (0.40) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL4439995 | 0.81 | PPARA (0.51) | CA1PPARACA2CA12CA7 | |
| SCHEMBL21217014 | 0.80 | CA1 (0.44) | CA1PPARAPSEN1PSEN2APH1B | |
| SCHEMBL18236676 | 0.80 | SAT1 (0.35) | CA1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | claimed |
| CN-103582642-B | HSP90 inhibitor | 索隆-基特林癌症研究协会 | 2021-05-11 | — | — | CN | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-9926321-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2018-03-27 | — | — | US | claimed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | claimed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | claimed |
| US-20140088121-A1 | HSP90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-03-27 | — | — | US | claimed |
| EP-2694505-A1 | HSP90 INHIBITORS | Sloan-kettering Institute For Cancer Research (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138894-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-10-11 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2023096928-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2023-03-21 | — | — | US | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-1629000-A4 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006122188-A2 | TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006086381-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1629000-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-1996024591-A1 | CYCLOALKYLSULPHONYL-AMINOSULPHONYL UREAS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088121-A1 | HSP90 Inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1982/4885PPARA 4221/4885PSEN1 3883/4885 |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AA1 | CA1 4402/4885PPARA 3440/4885PSEN1 4490/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | CA1 1994/4885PPARA 4204/4885PSEN1 3898/4885 |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AB2P | CA1 3627/4885PPARA 3942/4885PSEN1 3529/4885 |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | HSP90AB1, HSP90AA1, HSP90B1 | CA1 2122/4885PPARA 1920/4885PSEN1 4019/4885 |
| US-11607465-B2 | Uses of labeled HSP90 inhibitors | HSP90AB1, HSP90B1, HSP90AA1 | CA1 4402/4885PPARA 3440/4885PSEN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.